Maravai LifeSciences/$MRVI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Ticker

$MRVI
Primary listing

Industry

Life Sciences Tools & Services

Employees

580

ISIN

US56600D1072

MRVI Metrics

BasicAdvanced
$361M
-
-$1.16
0.19
-

What the Analysts think about MRVI

Analyst ratings (Buy, Hold, Sell) for Maravai LifeSciences stock.

Bulls say / Bears say

Maravai LifeSciences has expanded its capabilities by acquiring the DNA and RNA business of Officinae Bio, enhancing its mRNA design and manufacturing services. (nasdaq.com)
The company has entered into a partnership with VWR to distribute TriLink BioTechnologies' products across Europe, the Middle East, and Africa, potentially increasing its market reach. (nasdaq.com)
Maravai has appointed R. Andrew Eckert as independent Chairman of the Board, bringing experienced leadership to guide the company's strategic direction. (nasdaq.com)
The company reported a net loss of $259.6 million for the full year 2024, a significant increase from the previous year's loss of $138.4 million. (nasdaq.com)
Fourth quarter revenue decreased by 23.7% year-over-year, indicating a concerning decline in business performance. (nasdaq.com)
A goodwill impairment of $166.2 million was recorded for the Nucleic Acid Production segment, suggesting potential overvaluation of acquired assets. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.

MRVI Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MRVI Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRVI

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs